2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1403

Systematic Appraisal of the American College of Rheumatology Clinical Practice Guidelines

Quality Measures and Quality of Care - Poster II

9:00AM-11:00AM: Abstract Number: 1161

Systematic Development of a Patient-Centered Strategy to Improve Tight Control in Daily Clinical Practice

Education - ARHP Poster

9:00AM-11:00AM: Abstract Number: 1404

Systematic Review and Appraisal of Quality Measures for Inflammatory Arthritis

Quality Measures and Quality of Care - Poster II

9:00AM-11:00AM: Abstract Number: 1762

Systemic Lupus Erythematosus and the Evaluation of Poor Sleep

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

9:00AM-11:00AM: Abstract Number: 1760

Systemic Lupus Erythematosus in Immigrants: Results from the 1000 Canadian Faces of Lupus Study

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

9:00AM-11:00AM: Abstract Number: 1811

Systemic Lupus Erythematosus: Detailed Anatomy of a Cohort (follow-up for more than 35 years).

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

9:00AM-11:00AM: Abstract Number: 1323

Systemic Manifestations Associated with Parvovirus B19 Infection in Adults: A Retrospective Study in 23 Patients

Infection-related Rheumatic Disease - Poster

9:00AM-11:00AM: Abstract Number: 1907

T-Bet Regulates Ahr-Mediated Th-17 Differentiation Independently of IFNγ

T Cell Biology and Targets in Autoimmune Disease - Poster Session I

9:00AM-11:00AM: Abstract Number: 1097

Tankyrase Regulates Osteoclastogenesis Via SH3BP2

Biology and Pathology of Bone and Joint - Poster II

9:00AM-11:00AM: Abstract Number: 1125

Targeted Lipidomics Reveals Incomplete Activation of Resolution Pathways in Knee Osteoarthritis

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis - Poster I

9:00AM-11:00AM: Abstract Number: 1123

Targeted Mutations Identify the Active Site of Glucocorticoid-Induced Leucine Zipper (GILZ)

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis - Poster I

9:00AM-11:00AM: Abstract Number: 1213

Targeted Next-Generation Sequencing of 128 Genes Associated with Rheumatoid Arthritis

Genetics, Genomics and Proteomics - Poster II

9:00AM-11:00AM: Abstract Number: 1109

Targeting IL-8 and CXCR1/2 Abrogates RANKL- and ACPA-Mediated Osteoclastogenesis

Biology and Pathology of Bone and Joint - Poster II

9:00AM-11:00AM: Abstract Number: 1881

Targeting Oncostatin M in the Target Tissue: Assessment of in-Vivo Affinity and Target Engagement of an Anti-OSM Monoclonal Antibody By Combining Blood and Skin Blister Fluid Data

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II

9:00AM-11:00AM: Abstract Number: 1436

TAS8274, a Highly Selective Janus Kinase 3 Inhibitor, Demonstrates Potent Efficacy in an Animal Model of Rheumatoid Arthritis

Rheumatoid Arthritis – Animal Models - Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].